212574-88-4

Basic information

• Product Name: 1-mercapto-1,1-pentamethylenethan-2-ol
• Synonyms: 1-mercapto-1,1-pentamethylenethan-2-ol
• CAS NO: 212574-88-4
• Molecular Weight: 146.254
• Mol File: 212574-88-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-mercapto-1,1-pentamethylenethan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-mercapto-1,1-pentamethylenethan-2-ol(212574-88-4)
• EPA Substance Registry System: 1-mercapto-1,1-pentamethylenethan-2-ol(212574-88-4)

Safety Data

• Hazardous Substances Data: 212574-88-4(Hazardous Substances Data)

Upstream product

• 2043-61-0 cyclohexanecarbaldehyde 
• 52958-74-4 1-[(2-formylcyclohexyl)disulfanyl]cyclohexanecarbaldehyde 
• 212574-87-3 [1-(1-Hydroxymethyl-cyclohexyldisulfanyl)-cyclohexyl]-methanol 

Downstream Products

• 306776-33-0 C₇H₁₃NO₂S 
• 883716-66-3 5’-O-DMT-N²-isobutyryl-2’-deoxyguanosine-3’-O-(2-thio-4,4-pentamethylene-1,3,2-oxathiaphospholane) 
• 865716-19-4 5’-O-DMT-N⁶-benzoyl-2’-deoxyadenosine-3’-O-(2-thio-4,4-pentamethylene-1,3,2-oxathiaphospholane) 
• 212574-97-5 N-{9-[(2R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(3-oxa-1-thia-2-phospha-spiro[4.5]dec-2-yloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide 
• 212575-01-4 N-{9-[(2R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(3-oxa-1-thia-2-phospha-spiro[4.5]dec-2-yloxy)-tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-isobutyramide 
• 212574-99-7 N-{1-[(2R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(3-oxa-1-thia-2-phospha-spiro[4.5]dec-2-yloxy)-tetrahydro-furan-2-yl]-2-oxo-1,2-dihydro-pyrimidin-4-yl}-benzamide 
• 212574-95-3 1-[(2R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(3-oxa-1-thia-2-phospha-spiro[4.5]dec-2-yloxy)-tetrahydro-furan-2-yl]-5-methyl-1H-pyrimidine-2,4-dione 

Relevant articles and documents

Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates

A number of cytotoxic pyrrolobenzodiazepine (PBD) monomers containing various disulfide-based prodrugs were evaluated for their ability to undergo activation (disulfide cleavage) in vitro in the presence of either glutathione (GSH) or cysteine (Cys). A good correlation was observed between in vitro GSH stability and in vitro cytotoxicity toward tumor cell lines. The prodrug-containing compounds were typically more potent against cells with relatively high intracellular GSH levels (e.g., KPL-4 cells). Several antibody-drug conjugates (ADCs) were subsequently constructed from PBD dimers that incorporated selected disulfide-based prodrugs. Such HER2 conjugates exhibited potent antiproliferation activity against KPL-4 cells in vitro in an antigen-dependent manner. However, the disulfide prodrugs contained in the majority of such entities were surprisingly unstable toward whole blood from various species. One HER2-targeting conjugate that contained a thiophenol-derived disulfide prodrug was an exception to this stability trend. It exhibited potent activity in a KPL-4 in vivo efficacy model that was approximately three-fold weaker than that displayed by the corresponding parent ADC. The same prodrug-containing conjugate demonstrated a three-fold improvement in mouse tolerability properties in vivo relative to the parent ADC, which did not contain the prodrug.

Nucleoside 3'-O-(2-oxo-'spiro'-4.4-pentamethylene-1.3.2- oxathiaphospholane)s: Monomers for stereocontrolled synthesis of oligo(nucleoside phosphorothioate/phosphate)s

Attempts at synthesis of 'chimeric' oligonucleotide constructs (PO/PS- Oligos) possessing phosphate and P-stereodefined phosphorothioate internucleotide linkages via combined phosphoramidite/oxathiaphospholane methods were unsuccessful. Therefore, novel m